Blog
In the first half of the year, Qizheng Tibetan Medicine’s net profit excluding non-recurring items increased by 27.36%. The company plans to distribute a cash dividend of 2.2 yuan for every 10 shares in the interim period.
Release time:
2025-08-25 11:00
On the evening of August 22, Qizheng Tibetan Medicine disclosed its 2025 semiannual report. During the reporting period, the company’s performance grew steadily, with revenue reaching RMB 1.175 billion, an increase of 16.36% over the same period last year. Net profit attributable to shareholders of the listed company amounted to RMB 358 million, up 10.04% year-on-year; net profit attributable to shareholders of the listed company excluding non-recurring gains and losses was RMB 289 million, representing a year-on-year increase of 27.36%. Net cash flow from operating activities reached RMB 491 million, with a year-on-year growth rate of 993.71%.
For the company’s semi-annual profit distribution in 2025, the base for calculation will be the total number of outstanding shares as of the record date for the semi-annual profit distribution (excluding shares held in the treasury account). A cash dividend of RMB 2.20 per 10 shares (including tax) will be distributed to all shareholders.
During the reporting period, Qizheng Tibetan Medicine achieved further success with its comprehensive marketing strategy for multiple products. The company’s core product for the musculoskeletal system—Xiaotong Paste—focused on key hospitals and expanded its reach across multiple departments and disease types. The company deepened its engagement in orthopedics while closely collaborating with specialized departments such as rehabilitation, geriatrics, pain management, and general medicine, continuously increasing its coverage of both higher-level and grassroots hospitals. At the same time, the company significantly boosted its online channels, driving substantial growth in B2C and O2O sales. As a result, Xiaotong Paste’s market share continued to strengthen, providing stable support for the company’s overall business growth. In addition, products such as Bai Mai Ointment, Ruyi Zhenbao Tablets, and Qingpeng Ointment also contributed new growth drivers.
In the area of academic marketing, the company has conducted real-world studies across multiple therapeutic settings, focusing on strategic products such as Xiaotong Tie Gao (Pain Relief Patch), Bai Mai Ointment, Qing Peng Ointment, Hong Hua Ru Yi Wan (Red Flower Ruyi Pills), and Ru Yi Zhen Bao Pian (Ruyi Treasure Tablets). Among these, Xiaotong Tie Gao, Bai Mai Ointment, and Ru Yi Zhen Bao Pian have been included in the "Chinese Guidelines for the Diagnosis and Treatment of Cervical Degenerative Diseases," recommended by pain specialists from the China Association for Geriatric Health Care.
The company continues to advance the modernization of Tibetan medicine. During the reporting period, new drug development efforts progressed smoothly. The Phase III clinical trial for Bai Mai Ointment, a topical product in our external-use pipeline, has received ethical approvals from all participating research centers, and the clinical trial has now been fully launched. The CDE communication meeting regarding the application for Zheng Ru Tie has received feedback and is proceeding as planned. Commercial re-verification work for Cui Tang Granules, our respiratory-product pipeline, is ongoing. In May 2025, the innovative Class 1.1 drug, Xiao Er Re Li Qing Granules, received the Notice of Approval for Clinical Trials (2025LP01422). Currently, both Xiao Er Re Li Qing Granules and Zheng Ru Tie have entered the preparation stage for clinical sample production.
Reporting media: Shanghai Securities Journal – China Securities Net
Report link: https://www.cnstock.com/commonDetail/494131
Recommended News
2026-05-25
Copyright Qizheng Tibetan Medicine Co., Ltd. All rights reserved. ICP Filing Number:
Internet drug information service qualification certificate number:（藏） Non-Commercial - 2018-0004 SEO